Litigation Details for Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
✉ Email this page to a colleague
Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Docket | 1:17-cv-01772 | Date Filed | 2017-12-07 |
| Court | District Court, D. Delaware | Date Terminated | 2019-01-14 |
| Cause | 35:271 Patent Infringement | Assigned To | William C. Bryson |
| Jury Demand | None | Referred To | Mary Pat Thynge |
| Parties | CHIESI U.S.A., INC.; TEVA PHARMACEUTICAL INDUSTRIES LTD. | ||
| Patents | 6,987,094; 7,696,178; 7,939,502 | ||
| Attorneys | Katherine A. Daniel; Scott J. Bornstein | ||
| Firms | Shaw Keller LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Start Trial .
Details for Chiesi U.S.A., Inc. v. Teva Pharmaceuticals USA, Inc. (D. Del. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-12-07 | External link to document | |||
| 2017-12-06 | 1 | United States Patent Nos. 6,987,094 (“the ’094 patent”), 7,696,178 (“the ’178 patent”), and 7,939,502… This is a civil action for patent infringement arising under the patent laws of the United States, …’502 patent”), attached hereto as Exhibits A, B, and C, respectively (collectively, “the patents-in-suit…Farmaceutici S.p.A. owns the ’094 patent. 28. The ’178 patent, entitled “Optimized Formulation…Farmaceutici S.p.A. owns the ’178 patent. 29. The ’502 patent, entitled “Optimized Formulation | External link to document | |
| 2017-12-06 | 4 | the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,987,094; 7,696,178; 7,939,502…2017 14 January 2019 1:17-cv-01772 835 Patent - Abbreviated New Drug Application(ANDA) None | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
